Dianthus Therapeutics, Inc. (DNTH) Stock: Price, Forecast & Analyst Target
Dianthus Therapeutics, Inc. (DNTH) — MoonshotScore 27/100 (Weak band), calculated Nov 18, 2026. Price $84.83 (+1.01%), as of the Nov 19, 2026 trading session; market cap $4.78B.
Educational signal · not a buy or sell recommendation · How to read this
Dianthus Therapeutics, Inc. · DNTH · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune disease, with lead candidates in active development. The investment case depends on whether candidates can progress through clinical trials to approval and market adoption before the company's cash reserve diminishes.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Dianthus Therapeutics (DNTH)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but weak quality, weak growth and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $1M (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 4 of the last 8 reports
- Altman Z 84.55 · Piotroski F 2
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 26 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $84.83 | |
| Change on the day | +1.01% | |
| 52-week range | $35.84–$117.88 | |
| Market capitalisation | $4.78B | — |
| Price / earnings (trailing) | 102.15 | |
| Shares traded on the day | 815.5K | |
| Beta (volatility vs the S&P 500) | 0.08 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Dianthus Therapeutics (DNTH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Dianthus Therapeutics (DNTH), and what does it report?
Short answer · as of
Dianthus does not yet have an approved product or significant revenue.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The company's reporting shows the classic clinical-stage biotech profile: minimal revenue from a licensing agreement, and operating losses driven entirely by research and development spending. The lead clinical candidate, claseprubart, is a monoclonal antibody engineered to target the active form of the complement protein with extended half-life and high selectivity, addressing complement-mediated inflammation in severe autoimmune conditions.
A second candidate targets plasmacytoid dendritic cells to suppress interferon production and suppress B cell function. Both are designed for conditions where few alternatives exist, which typically supports higher prices if approved.
What do the latest results show for Dianthus Therapeutics (DNTH)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1M.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The most recent quarter showed the highest cash burn rate the company has recorded. Research and development spending climbed sharply while revenue remained minimal and unstable, driven by the small licensing agreement with no growth visible in the near term. This acceleration reflects the company's movement deeper into clinical development, which is expected to become even more capital-intensive as trials expand.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1M | -$47M | -$0.81 (diluted) |
| Q2 FY2026 | $761,000 | -$50M | -$0.90 (diluted) |
| Q1 FY2026 | $463,000 | -$41M | -$0.85 (diluted) |
| Q4 FY2025 | $284,000 | $98M | $2.59 (diluted) |
What are the financial strengths and risks for Dianthus Therapeutics (DNTH)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The company's major strength is the absolute scale of its cash reserve relative to the quarterly burn rate, which covers the projected timeline through the expected approval decision. Debt is nearly nonexistent, leaving cash as the only material liability. The central risk is the clinical and commercial success of the lead candidates; a failure in trials or poor market uptake would eliminate substantially all shareholder value. A secondary risk is that the burn rate will accelerate further or that the timeline to approval will extend, eroding the margin of safety that the current reserve provides.
Data-derived red flags
- Negative return on equity (-3.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 102.15 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Dianthus Therapeutics (DNTH)?
Short answer · as of
Current published price targets run low $122.00 · high $158.00 · consensus $136.50 · median $133.00 against a quoted price of $84.83 (as of Nov 19, 2026).
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Watch for clinical trial progression updates on leading candidates. The path to profitability requires approval and market adoption of the lead programs. Management's ability to preserve cash and extend runway through the approval decision is critical; any substantial deviation from the projected burn rate should trigger reassessment.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Dianthus Therapeutics compare with its peers?
Short answer
Dianthus Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Dianthus differs from stable pharmaceutical companies because it has no approved products and minimal revenue. It resembles other clinical-stage immunology companies in that its value is entirely contingent on clinical success. The focus on severe autoimmune indications narrows the addressable market compared to companies pursuing broader conditions, but the unmet medical need typically supports higher prices upon approval.
| Company | Price | Market value | Score |
|---|---|---|---|
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $942.04 Nov 19, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $41.37 Nov 18, 2026 | $4.53B | 84 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $44.89 Nov 18, 2026 | $3.30B | 72 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $13.76 Nov 18, 2026 | $4.83B | 67 5-pillar Nov 18, 2026 | |
| $95.74 Nov 18, 2026 | $6.49B | 67 5-pillar Nov 18, 2026 | |
| $124.86 Nov 18, 2026 | $5.27B | 66 5-pillar Nov 18, 2026 | |
| $26.62 Nov 18, 2026 | $3.42B | 66 5-pillar Nov 18, 2026 | |
| Dianthus Therapeutics (DNTH) — this page | $84.83 | $4.78B | 27 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $122.00 – $158.00
- Consensus target
- $136.50
- Median target
- $133.00
Consensus record · Captured .
Measured against a quoted price of $84.83 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 105
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 47
- Other transactions
- 58
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DNTH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DNTH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Dianthus Therapeutics (DNTH)?
- Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
- Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,118,555.02 in Stock
- Dianthus Therapeutics Insider Sold Shares Worth $11,228,720, According to a Recent SEC Filing
- Dianthus Therapeutics (DNTH) Stock May Look Stretched As Pipeline Progress Draws Focus
DNTH Healthcare Stock FAQ
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What complement blockade program is Dianthus advancing?
The lead program blocks the active form of the complement protein, designed to suppress complement-driven inflammation in severe autoimmune conditions. A bifunctional fusion protein works through a distinct mechanism, suppressing interferon production and B cell activity. Both address indications with substantial unmet need; the company's rising research spending reflects the development intensity required, and analyst estimates for future revenue reflect expectations of clinical success.
How long can the company operate with its current cash and burn rate?
The company's cash reserve, when divided by the current quarterly operating cash consumption, extends the runway to a date well into the projected conclusion of clinical trials. If trials take longer or burn accelerates, this timeline shortens.
Why have insiders been selling shares?
Form filings show significant insider selling in recent periods from company leadership, with no offsetting purchases. Form data records only the transaction, not the reason, but such sales often reflect vesting taxation rather than loss of confidence. Analyst coverage remains uniformly positive despite this selling pattern, providing context to interpret the activity.
What do analysts expect for future revenue?
Analyst consensus projects minimal revenue in the near term, reflecting the expectation that the lead candidates remain in trials. Revenue estimates then expand significantly in the out years, conditional on regulatory approval and market uptake. The wide range between high and low estimates reflects the inherent uncertainty of clinical-stage biotech.
What is the DNTH stock price today?
The last price recorded for Dianthus Therapeutics, Inc. (DNTH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DNTH price target?
The analyst consensus price target for Dianthus Therapeutics, Inc. (DNTH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com